Publication | Closed Access

OA-05 Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): analysis of patient and disease-related factors associated with responses

Hematological MalignancyOncologyGprc5dxcd3 Bispecific AntibodyImmunologyImmune Checkpoint InhibitorOa-05 EfficacyImmunotherapyMedicineRelapsed/refractory Multiple Myeloma